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Introduction
The treatment of bradycardia by implantation of an artificial cardiac pacemaker is a routine procedure associated with extended longevity for those with atrio-ventricular (AV) block [1] [2] and improved quality of life for patients with sick sinus syndrome.
[3] However, long term right ventricular (RV) pacing is associated with adverse remodelling of the left ventricle, [4] which can contribute to or cause left ventricular systolic dysfunction (LVSD), [5] or overt heart failure. [6] In prospective studies of patients receiving standard RV pacemakers, subsequent hospitalisation for heart failure varies from 10% to 26%, [6] [7] possibly, although not consistently, [8] related to the amount of RV pacing delivered, [6] and baseline features such as the presence of impaired left ventricular (LV) function, atrial fibrillation and older age at implant [7] [9] and paced QRS.
[10] In a cross-sectional study in patients attending a pacemaker follow-up clinic we have previously demonstrated a prevalence of heart failure symptoms with LVSD of 27%. [11] One third of all pacemaker procedures are to replace an expired existing pacemaker generator, and this proportion is increasing.
[12] These patients might be at even higher risk for underlying LVSD and heart failure in view of their older age, longer duration of RV pacing, and underlying cardiac disease.
The time of a pulse generator replacement (PGR) presents an opportunity to review symptoms, LV function, medical therapy and device prescription, but this is rarely done. [13] We therefore undertook this pragmatic prospective observational study to assess the prevalence and associations of LV dysfunction in patients with long-term RV pacemakers booked for an elective generator replacement. Committee (08/H1307/12).
Methods

All
Results
Of the 508 patients undergoing pacemaker generator replacement in the study period, we collected a complete dataset on 491 (97%). Patients not assessed (or in whom data-points were missing) were not different in terms of age, pacemaker variables or co-morbidities. Table 1 shows demographic and basic pacemaker data. Cardiovascular co-morbidities (43% had overt ischaemic heart disease, 27% atrial fibrillation and 13% diabetes mellitus) and concurrent cardiovascular medical therapies were common. Table 2 p<0.0001) than those without CHB at baseline, and although 78% of those with CHB at baseline had >80%VP at PGR, 12% had less than 40%VP at follow-up. Furthermore, 37% of patients implanted for AV block but not CHB at baseline were receiving >80%VP at the time of PGR.
DEVICE PRESCRIPTION AND PROGRAMMING
There was a weak correlation between age and %VP, (r=0. Table 2 shows the results of non-invasive testing in patients attending for PGR. The mean and median LVEF were both 50% and the range was 12-
74%. An interaction plot demonstrated that mean LVEF was only significantly lower in patients with %VP>80% so we used this as our cut off for further analyses. The prevalence of LV dysfunction (LVEF<50%) was 40% in our cohort, but this was significantly higher in those with i) >80%VP (59%) compared with <80%VP (22%)(p<0.0001) and ii) those with cardiovascular co-morbidities (figure 1 were dead (n=34) or had been hospitalised (n=22) for heart failure.
Univariable predictors of mortality or hospitalisation for heart failure are shown in Table 4 . On multivariable analysis, previous myocardial infarction and high th 2014; Version R1.0
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Page 10 of 19 %VP were independently associated with a worse survival. The Kaplan Meier curves for patients with and without LVEF <50% and with and without %VP>80% are shown in Figure 3 .
Discussion
The present data, the first to explore systematically a contemporary cohort of patients undergoing standard pacemaker generator replacement, demonstrate a high prevalence of LV dysfunction and cardiovascular comorbidity and a mortality rate only modestly lower than that of heart failure patients of similar age. [14] The presence of LV dysfunction is independently related to the amount of RV pacing and, particularly when combined with a high percentage of ventricular pacing, LV dysfunction portends an adverse prognosis.
In retrospective analyses [16] [17] and one prospective study 
Management of RV-pacing associated LV dysfunction
Studies exploring the medical management of patients with pacemakers and LV dysfunction are rare, [23] and although patients with pacemakers and heart failure were not excluded from all trials of medical therapy, subgroup analysis of the paced population was not undertaken in any of the large studies. For example whether, in a patient with LVSD and a pacemaker, the benefit of high-dose -blockers compensates for the adverse effects of ventricular pacing is unknown.
Since RV pacing contributes to poorer outcomes, [24] Reprogramming is not an option in heart failure patients with standard pacemakers with complete heart block or a slow response to atrial fibrillation. Upgrading to CRT at the time of PGR those patients with a high percentage of pacing and LV systolic dysfunction (LVEF<50%) but few symptoms improves quality of life, LV function, and exercise capacity while reducing NT-pro-B-type natriuretic peptide, and might reduce heart failure events, [34] but larger studies are required to provide data on hard endpoints. A registry of successful upgrades, although useful, is not enough. [35] Preventing RV pacing-associated LV dysfunction modestly predicts high %VP at long term follow-up, yet 65% of patients with AV node disease but without CHB at implant go on to >80%VP. Hence CHB at baseline represents only 80% of those eventually requiring >80%VP. [36] Also, despite high %VP, some patients in our cohort seem resistant to the adverse effects of RV apical pacing. Since CRT at baseline does not universally prevent a deterioration in LV function, [37] the benefits of prophylactic CRT versus RV pacing in an unselected population may be marginal, [38] requiring careful risk stratification to identify patients in whom CRT for bradycardia is cost-and clinically-effective. The Biventricular versus
Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) study, [39] set out to determine whether CRT for bradycardia is better than standard RV pacing in patients with mild LVSD (EF<50%).
Patients receiving biventricular pacing had lower rates of death from any cause, urgent heart failure care or increase in left ventricular end systolic volume index (LVESI) of >15% from baseline. However, the study included patients with an existing CRT indication (30% had LVEF<35% and mean QRS duration was 125ms), for whom 'standard care' meant high rates of RV pacing with the additional upfront higher risk of a CRT pacemaker implantation. Some patients may have experienced more adverse events than would be expected with a dual chamber pacemaker programmed to avoid pacing. The lack of a control arm (all patients received a CRT device with the LV lead deactivated in those randomised to standard RV pacing) means that cost-benefit and cost-utility analyses cannot be done. [40] One large randomised study looking at the effects on morbidity and mortality of CRT versus RV pacemaker systems in patients with a bradycardia has completed recruitment. [41] Although there is growing enthusiasm for right ventricular septal pacing there are as yet no hard endpoint data to support widespread adoption of this strategy. [42] [36]
Limitations
The present data do not include patients with new implants that did not survive to generator replacement, and therefore represent a selected population. However, even these 'survivors' have an appreciable subsequent morbidity and mortality so a generator replacement procedure might be an appropriate time point to review medical and device therapy.
Merely diagnosing the presence of LVSD might have led to changes in therapy and programming and therefore outcomes. A future study might benefit from randomisation to provide a cohort of 'usual care' patients who do not undergo echocardiography.
We also excluded from our analysis of survival, the 25 patients with LVSD and high %VP that consented to be enrolled into a study of cardiac resynchronisation versus standard generator replacement. This might have served to reduce the degree of morbidity and mortality associated with high amounts of RV pacing and LVSD in our cohort.
By demonstrating a dose-response relationship between the amount of ventricular pacing and the degree of LV dysfunction, we have fulfilled one of the requirements for causality. [43] We appreciate that we do not have echocardiographic data on our patients at the time of their first pacemaker implantation. Hence we cannot comment on whether, and in what circumstances, RV pacing induces LV dysfunction. Our stated aim was not however, to identify features at baseline that predict future LVSD, rather our aim was to provide a platform with which to stratify risk in order to identify those patients with existing pacemakers in whom further investigation might be of most benefit.
Our dataset and the analysis, although prospectively collected cannot account for unknown confounders and our findings along with our risk model require validation and refining in future larger internal and external cohorts. 
Conclusions
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